VKTX Company Profile and Key Details

Q: Who are the executives of VKTX?

Mr. Michael MorneauVice President of Fin. & Admin.Dr. Brian Lian Ph.D.Pres, Chief Executive Officer & DirectorMr. Gregory S. ZanteChief Financial OfficerMs. Marianne ManciniChief Operating OfficerDr. Geoffrey E. Barker Ph.D.Senior Vice President of Pharmaceutical Devel.

NASDAQ : VKTX

Viking Therapeutics

$33.12

-0.63-1.87%

At Close 4:00 PM

55.83

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Viking Therapeutics, Inc. (VKTX) stock declined over -1.87%, trading at $33.12 on NASDAQ, down from the previous close of $33.75. The stock opened at $33.49, fluctuating between $33.08 and $34.38 in the recent session.

Stock Snapshot

33.75

Prev. Close

3.83B

Market Cap

33.08

Day Low

-10.38

P/E Ratio

-3.19

EPS (TTM)

-0.73

Cash Flow per Share

33.49

Open

115.55M

Number of Shares

34.375

Day High

97.02%

Free Float in %

3.48

Book Value

1.69M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 25, 2026	33.44	34.38	33.08	33.12	1.69M
Feb 24, 2026	33.65	34.56	33.25	33.75	2.25M
Feb 23, 2026	32.60	35.73	32.50	34.46	5.66M
Feb 20, 2026	30.69	31.20	30.19	31.03	1.78M
Feb 19, 2026	29.97	31.19	29.72	31.10	2.11M
Feb 18, 2026	30.30	31.22	29.85	30.15	2.23M
Feb 17, 2026	29.37	31.19	28.80	30.45	2.79M
Feb 13, 2026	30.72	31.00	28.75	29.00	2.93M
Feb 12, 2026	33.74	34.38	30.18	30.49	8.57M
Feb 11, 2026	28.52	28.98	27.17	28.55	3.87M
Feb 10, 2026	29.10	29.70	28.64	28.75	1.92M
Feb 09, 2026	28.69	29.67	27.86	29.30	2.66M
Feb 06, 2026	27.51	28.47	26.89	28.44	3.68M
Feb 05, 2026	28.11	28.64	25.77	26.29	5.72M
Feb 04, 2026	29.53	29.66	28.01	29.56	3.21M
Feb 03, 2026	30.40	30.80	28.56	29.41	2.77M
Feb 02, 2026	28.65	30.25	28.55	29.92	2.53M
Jan 30, 2026	30.34	30.59	28.95	29.04	3.53M
Jan 29, 2026	30.28	30.81	29.92	30.24	1.66M
Jan 28, 2026	31.49	31.49	30.07	30.41	2.89M

Contact Details

San Diego, CA 92121

United States

https://www.vikingtherapeutics.com 858 704 4660

About Company

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR�), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR� for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Stock Peers

ARGX

-23.33-2.78%

argenx SE$816.95 REGN

12.09+1.57%

Regeneron Pharmaceuticals, Inc.$784.28 UTHR

61.67+13.03%

United Therapeutics Corporation$535.10 VRTX

-4.38-0.90%

Vertex Pharmaceuticals Incorporated$483.05 MDGL

-4.99-1.13%

Madrigal Pharmaceuticals, Inc.$435.01 PRAX

4.84+1.41%

Praxis Precision Medicines, Inc.$347.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.49-1.65%

Alnylam Pharmaceuticals, Inc.$327.36 KRYS

5.6+2.10%

Krystal Biotech, Inc.$272.50 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Viking Therapeutics, Inc. (NASDAQ:VKTX) closed at $33.12 USD, losing -$0.63 (-1.87%) from the previous close of $33.75. The stock is currently mid-range between its 52-week high and low $18.92 and $43.15. With a market capitalization of about $3.83 billion, Viking Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 2.97 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Viking Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brian Lian, the company employs approximately 45 people and listed since April 28, 2015. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Technical Performance

VKTX has shown mixed momentum, gaining 5.54% over the past week and -0.04% over the past quarter, though year-to-date performance is down -4.72%. Short-term trend indicators are mixed aligned (SMA20 9.77%, SMA50 1.97%, SMA200 5.32%). The stock’s 14-day RSI is 56.17 (neutral), while the ATR of 2.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.24% below its high and over 75.05% above its low. Average 10-day trading volume of 2.64 million shares is below the 3-month average of 2.97 million, indicating normal recent market interest.

Valuation Metrics

Viking Therapeutics, Inc. trades at a P/E ratio of -10.56, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.94 trading at moderately above to book value. The P/FCF stands at -13.81, also below market averages.

Dividend & Fair Value

Viking Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.47. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Viking Therapeutics, Inc. generated EPS of -$3.18 over the past year. Five-year average earnings growth is -42.46%. Wall Street analysts project EPS growth of -9.28% annually over the next five years. The latest quarter delivered EPS of -$0.81. The next quarter is forecast at -$1.00. Next year's EPS is expected at -$17.22. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 8 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $125.00 to $30.00. The high target offers 277.42% upside. The low target suggests -9.42% downside. The mean target is $94.21. This offers 184.45% upside. Viking Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended October 22, 2025, missed forecasts by 15.71%. The prior quarter beat by 31.82%. Over the last six quarters, Apple has recorded several small beats. These include -22.48% in July 24, 2024.

Shareholding & Insider Activity

Viking Therapeutics, Inc. has 112.44 million shares outstanding. The public float is 219.96 million shares, elevated short interest at 28.46% of float. This equals 26.68 million shares. The short ratio is 3.05 days. Institutional investors hold 67.18% of the float. Insiders own 2.17%. LIGAND PHARMACEUTICALS INC holds 5.82 million shares, Lian Brian has 2.50 million shares and Mancini Marianna has 409.19 thousand shares. Over the past six months, insider transactions show net selling. They sold 136.86 thousand shares across 8 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Viking Therapeutics has not generated any revenue. Returns are negative, with ROA at -23.31% and ROE at -24.65%.
On valuation metrics, Viking Therapeutics trades at a P/E of -10.56, P/S of 0.00 and P/B of 5.94. The current ratio is 9.33 and quick ratio is 9.33. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -93445.26 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -2034.20.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Viking Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $292.00K (margin 0.00%). Operating income was - $100.83M (margin 0.0%). Net income was- $85.90M (EPS - $0.91).
The company ended the quarter with $362.08M in cash and short-term investments, a total debt of $1.26M, and net debt of - $54.26M. Total assets were $368.49M, with equity of $348.42M. Financials further reflected weakness, with operating cash flow of - $73.38M, free cash flow of - $73.38M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Viking Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.08%, with price expected at $34.14 by March 11, 2026, within a range of $32.35 to $36.02 3-Month Outlook: Projected rise of 12.71%, reaching $37.33 by May 25, 2026, with a range of $34.15 to $39.93. 1-Year Outlook: Projected gain of 39.37%, with price at $46.16 by February 25, 2027, within a range of $37.92 to $52.90.

Key Takeaways

Viking Therapeutics, Inc. (NASDAQ:VKTX) shares are flat -4.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Viking Therapeutics, Inc. trading at a premium to the broader market with a P/E of -10.56. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $65.26, suggesting 97.04% upside. Our AI forecast model points to short-term strength (3.08% over two weeks), a medium-term rise (12.71% over three months), and a longer-term gain (39.37% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Viking Therapeutics, Inc. (VKTX) stock price?

Viking Therapeutics, Inc. (NASDAQ: VKTX) stock price is $33.12 in the last trading session. During the trading session, VKTX stock reached the peak price of $34.38 while $33.08 was the lowest point it dropped to. The percentage change in VKTX stock occurred in the recent session was -1.87% while the dollar amount for the price change in VKTX stock was - $0.63.

VKTX's industry and sector of operation?

The NASDAQ listed VKTX is part of Biotechnology industry that operates in the broader Healthcare sector. Viking Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VKTX?

Mr. Michael Morneau
Vice President of Fin. & Admin.
Dr. Brian Lian Ph.D.
Pres, Chief Executive Officer & Director
Mr. Gregory S. Zante
Chief Financial Officer
Ms. Marianne Mancini
Chief Operating Officer
Dr. Geoffrey E. Barker Ph.D.
Senior Vice President of Pharmaceutical Devel.

How VKTX did perform over past 52-week?

VKTX's closing price is 75.05% higher than its 52-week low of $18.92 where as its distance from 52-week high of $43.15 is -23.24%.

How many employees does VKTX have?

Number of VKTX employees currently stands at 45.

Link for VKTX official website?

Official Website of VKTX is: https://www.vikingtherapeutics.com

How do I contact VKTX?

VKTX could be contacted at phone 858 704 4660 and can also be accessed through its website. VKTX operates from 9920 Pacific Heights Boulevard, San Diego, CA 92121, United States.

How many shares of VKTX are traded daily?

VKTX stock volume for the day was 1.69M shares. The average number of VKTX shares traded daily for last 3 months was 2.97M.

What is the market cap of VKTX currently?

The market value of VKTX currently stands at $3.83B with its latest stock price at $33.12 and 115.55M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	45
Beta	0.77
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VKTX Company Profile and Key Details

Viking Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Earnings & Analyst Outlook

Shareholding & Insider Activity

Price Forecast & Outlook

Key Takeaways

Valuation Metrics